Proteomics

Dataset Information

0

Multiomics Characterization of Potential Therapeutic Vulnerabilities in Low-grade Serous Ovarian Carcinoma


ABSTRACT: Fourteen LGSOC cell lines were interrogated using whole exome sequencing, RNA sequencing, and mass spectrometry-based proteomics. Somatic mutation, copy-number aberrations, gene and protein expression were analyzed and integrated using different computational approaches. LGSOC cell line data was compared to publicly available LGSOC tumor data (AACR GENIE cohort), and also used for predictive biomarker identification of MEK inhibitor (MEKi) efficacy. Protein interaction databases were evaluated to identify novel therapeutic targets.

INSTRUMENT(S): Orbitrap Fusion

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Cell Culture

SUBMITTER: Gian Luca Negri  

LAB HEAD: Gregg Morin

PROVIDER: PXD019544 | Pride | 2021-05-17

REPOSITORIES: Pride

Dataset's files

Source:
Action DRS
TMT_layout.txt Txt
sc_27Feb2018_AD_OvC_profiling_A1.raw Raw
sc_27Feb2018_AD_OvC_profiling_A10.raw Raw
sc_27Feb2018_AD_OvC_profiling_A11.raw Raw
sc_27Feb2018_AD_OvC_profiling_A12.raw Raw
Items per page:
1 - 5 of 40
altmetric image

Publications


Low-grade serous ovarian carcinoma (LGSOC) is a rare tumor subtype with high case fatality rates in patients with metastatic disease. There is a pressing need to develop effective treatments using newly available preclinical models for therapeutic discovery and drug evaluation. Here, we use multiomics integration of whole-exome sequencing, RNA sequencing, and mass spectrometry-based proteomics on 14 LGSOC cell lines to elucidate novel biomarkers and therapeutic vulnerabilities. Comparison of LGS  ...[more]

Similar Datasets

2011-03-23 | E-GEOD-28131 | biostudies-arrayexpress
2021-12-22 | PXD020764 | Pride
2009-04-29 | E-GEOD-5073 | biostudies-arrayexpress
2020-01-09 | PXD016021 | Pride
2020-02-11 | E-MTAB-7084 | biostudies-arrayexpress
2014-09-16 | E-GEOD-61416 | biostudies-arrayexpress
2017-01-30 | E-MTAB-4667 | biostudies-arrayexpress
2023-01-27 | PXD031518 | Pride
2017-08-08 | PXD005904 | Pride
2022-11-28 | PXD036976 | Pride